Expert Ratings for Rani Therapeutics Hldgs
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Rani Therapeutics Hldgs (NASDAQ:RANI) in the last quarter, with an average price target of $19.75, implying significant upside from the current price of $4.1. However, this average has decreased by 3.66% from the previous average price target of $20.50.
August 21, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts are bullish on Rani Therapeutics Hldgs, with an average price target of $19.75, indicating a significant potential upside from the current price of $4.1.
The bullish ratings from analysts indicate a positive outlook for Rani Therapeutics Hldgs. The average price target of $19.75 is significantly higher than the current price of $4.1, suggesting that analysts believe the stock has substantial room for growth. However, the decrease in the average price target from $20.50 to $19.75 may suggest some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100